Lymphoma
Conditions
Keywords
contiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, stage III adult diffuse large cell lymphoma, stage IV adult diffuse large cell lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells. It is not yet known whether giving GM-CSF together with vaccine therapy is more effective than giving GM-CSF together with a placebo when given after combination chemotherapy and rituximab in treating diffuse large B-cell lymphoma. PURPOSE: This randomized phase III trial is studying GM-CSF and vaccine therapy to see how well they work compared to GM-CSF and placebo when given after combination chemotherapy and rituximab as first-line therapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma.
Detailed description
OBJECTIVES: Primary * Compare the 3-year disease-free survival of patients with high-intermediate- or high-risk bulky stage II or stage III or IV diffuse large B-cell lymphoma treated with sargramostim (GM-CSF) with or without autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId®) after combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R). Secondary * Compare the 2-year disease-free survival, duration of response, time to progression, overall survival, and safety in patients treated with these regimens. * Estimate the rate of immune reactivity to FavId®. OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to risk score (3 \[high-intermediate\] vs 4 or 5 \[high\]). * Chemotherapy: Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV, vincristine IV, and rituximab IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. * Sargramostim (GM-CSF) with or without autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId®): Patients achieving complete remission (CR) or unconfirmed CR after chemotherapy and who have FavId® available are randomized to 1 of 2 treatment arms. * Arm I: Patients receive FavId® vaccine subcutaneously (SC) on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4. * Arm II: Patients receive placebo SC on day 1 and GM-CSF SC as in arm I. In both arms, treatment repeats once a month for 6 months and then once every 2 months for 24 months (18 total vaccinations) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 2 years. PROJECTED ACCRUAL: A total of 480 patients will be accrued for this study.
Interventions
DRUGcyclophosphamide
DRUGdoxorubicin hydrochloride
DRUGprednisone
DRUGrituximab
DRUGsargramostim
DRUGvincristine
PROCEDUREIntervention/procedure
PROCEDUREantibody therapy
PROCEDUREbiological therapy
PROCEDUREchemotherapy
PROCEDUREcolony-stimulating factor therapy
PROCEDUREcytokine therapy
PROCEDUREmonoclonal antibody therapy
PROCEDUREtherapeutic procedure
PROCEDUREtumor cell derivative vaccine
PROCEDUREvaccine therapy
Sponsors
Favrille
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed diffuse large B-cell lymphoma * Bulky stage II or stage III or IV disease * Treatment naïve * International Prognostic Index score of 3 (high-intermediate) or 4/5 (high) * Lymphoma accessible for sampling or existing biopsy material judged suitable for preparation of autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId®) * No history of CNS lymphoma or meningeal lymphomatosis * No history of indolent lymphoma PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Platelet count \> 75,000/mm\^3 * ALT and AST \< 2 times upper limit of normal * Not pregnant or nursing * No history of unresolved hepatitis B viral infection * No history of a treated prior malignancy unless in remission ≥ 2 years, except for treated nonmelanoma carcinomas of the skin or in situ cervical carcinomas or prostatic carcinomas * No contraindication to doxorubicin hydrochloride (e.g., abnormal contractility on ECG) * No contraindication to vincristine (e.g., peripheral neuropathy) * No know HIV positivity * No serious nonmalignant disease, including any of the following: * Psychiatric disorders * Compromised pulmonary function * Congestive heart failure * Active bacterial, viral, or fungal infections PRIOR CONCURRENT THERAPY: * No prior keyhole limpet hemocyanin * No planned radiotherapy during or after study therapy * No concurrent systemic immunosuppressive therapy (e.g., steroids)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival as measured by the Kaplan-Meier method at 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival as measured by the Kaplan-Meier method at 2 years | — |
| Duration of response (complete or partial response) | — |
| Overall disease-free survival | — |
Countries
United States
Outcome results
None listed